30-04-2025 18:08 via medpagetoday.com

Immunotherapy/BCG Combo Boosts EFS in Non-Muscle Invasive Bladder Cancer

(MedPage Today) -- LAS VEGAS--Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus Calmette-Guérin (BCG)...
Read more »

Medical Industry news



Many Doctors Would Consider Assisted Dying at Their End of Life
Arizona Has Its First Measles Outbreak of the Year
Senators Grill Bhattacharya on Deep NIH Cuts in Proposed Budget
Fish Oil No Help for Kidney Function in Transplant Recipients
AMA Calls for Senate Investigation of RFK Jr.
FDA Restricts Use of Immunotherapies in Gastric, Esophageal Cancers
Less Real-World GLP-1 Weight Loss; TROA Support; Rebuttal to Vitamin D Guidelines
Targeting Food Dyes Ignores the Real Crisis in Childhood Nutrition
Sleep and Alzheimer's Risk; Brain Death Conversations; Faster Aging in Kids With MS
RFK Jr. Aide Attacks Health System but Runs Company Promoting Wellness Alternatives
Private Equity in Heart Failure Care; Oral PCSK9 Inhibitor Wins; First Robotic TAVR
Should AMA 'Support' a Registry to Track Side Effects of GLP-1 Drugs?
The AMA Could Have Spoken Louder About Politicization, Board Chair Says
CT Colonography Tops Stool DNA Testing for Colorectal Cancer Screening
Desktop versie